Health Equity and Clinical Research

The Benefits and Challenges of Conducting a Cost of Illness Study on Postoperative Analgesics Evaluating the Price of Pain: The Benefits and Challenges of a Cost of Illness Study on Postoperative Analgesics "The integration of costs, consequences, and effectiveness are key in making better decisions, particularly in healthcare. As professionals, it's crucial to understand the full extent of interventions to improve patients' lives and system efficiency." - Dr. Jim Weinstein After surgery, experiencing pain is a frequent and severe issue. It can result in various adverse consequences, such as slower recovery, higher chances of complications, and lower patient contentment. Pain relievers like opioids, non-opioids, and adjuvant medications are available after surgery. Opioids are effective but can have severe side effects like respiratory depression and constipation. Choosing a pain reliever depends on the surgery type, medical history, and individual preferences. A cost...

The Critical Role of Non-Narcotic Postoperative Pain Management in a Value-Based Care System Elevating Patient Outcomes in a New Healthcare Paradigm "In healthcare, we have to have a sense of urgency. People are counting on us. We have to act as though somebody's life depends on us...because somebody's life does depend on us."  - Dr. David Feinberg The previous article discussed various current and near-future types of non-narcotic postoperative analgesia. This article will explore how these non-narcotic postoperative pain management strategies fit into the Value-Based Care (VBC) model and why they are critical for its success. This sentiment is ever more pertinent as the healthcare industry makes an epochal shift towards a Value-Based Care (VBC) system. With this system, healthcare is not about the number of treatments but about the quality of outcomes, and it is here that non-narcotic postoperative pain management comes to the forefront. Immediate Benefits: Beyond P...

Non-Narcotic Postoperative Analgesia: Current Methods and Future Prospects Charting the Progress in Pain Management " Better is possible. It does not take genius. It takes diligence. It takes moral clarity. It takes ingenuity. And above all, it takes a willingness to try. "  - Dr. Atul Gawande Postoperative pain, a common and often debilitating experience, can significantly interfere with a patient's recovery from surgery and return to normal activities. In the past, doctors prescribed opioids like morphine and hydrocodone to treat this type of pain. While effective, these medications carry severe risks, including addiction, overdose, and respiratory depression. This reality has catalyzed a paradigm shift towards non-narcotic analgesics for postoperative pain management. As the first part of our series on "Transforming Postoperative Pain Management: Innovations, Implications, and the Future," we delve into these non-narcotic alternatives that offer fewer side ef...

The Transformative Power of Clinical Trial Referrals in Non-Academic Practices "Alone, we can do so little; together, we can do so much."  - Helen Keller In the rapidly evolving healthcare landscape, the referral of patients from non-academic medical practices to clinical trials emerges as a potent collaborative strategy. The benefits of this referral mechanism ripple beyond individual interactions, impacting all stakeholders positively – the referring physician, the patient, and the Principal Investigator (P.I.) and Sub-Investigator (Sub I). Organizations facilitating this process and the pharmaceutical companies sponsoring these trials play instrumental roles in this ecosystem. For the Referring Physician and Patients Referring patients to clinical trials brings many advantages to physicians outside academic medical centers. It allows them to provide their patients' access to potentially groundbreaking treatments and a unique opportunity to stay updated with the latest ...

"Health is a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity."  - World Health Organization The Health Equity Imperative A stark reality was exposed during the COVID-19 pandemic – deep-seated healthcare disparities that predominantly impact communities marginalized by race, income, gender, and geography. But could this crisis also provide us a roadmap to fostering health equity? Can tools within the pharmaceutical industry like Health Economics and Outcomes Research (HEOR) and Real World Evidence (RWE) hold the keys to addressing these disparities? The Current Landscape: A Divide Laid Bare Consider Mary, a single mother of three living in a low-income neighborhood. She's juggling two jobs and trying to keep her family safe during a global pandemic. Telemedicine could provide an excellent resource for Mary, but poor internet connectivity and limited technological literacy prove to be insurmountable barriers. How ...

  Pharmaceutical companies have a unique role to play in our society – not just supplying vital medicines, but also in contributing to the socio-economic health of our communities."   - Emma Walmsley, CEO of GlaxoSmithKline.   In today's evolving world, the social determinants of health (SDOH) are gaining widespread recognition for their role in health outcomes. These determinants encompass a variety of factors that influence health outcomes, including economic stability, education, social and community context, health and healthcare, and neighborhood and built environment. They are the conditions in which people live, grow, work, and age. From CDC For far too long, the focus of healthcare, and more so the pharmaceutical industry, has been centered around the development and distribution of therapeutics. However, an emerging perspective urges the industry to look beyond this traditional role. As stakeholders in the ecosystem of healthcare, pharmaceutical l companies shou...

    Diversity in Clinical Trials: A Strategic and Economic Game-Changer? Editorial by Brian J. Stowell "We are not makers of history. We are made by history."  - Dr. Martin Luther King Jr. Introduction In the evolving landscape of clinical trials, supplier and patient diversity programs are no longer seen as merely ethical or compliance requirements—they are strategic imperatives. They enhance the overall efficacy of clinical trials, influence competitive differentiation, and contribute to economic growth. This article will unravel how these diversity programs can provide a strategic advantage, deliver measurable economic benefits, and, most importantly, improve health outcomes for diverse patient populations. Supplier Diversity Programs Supplier diversity programs encourage the inclusion of diverse suppliers, such as minority-owned, women-owned, and small businesses, in the procurement process for clinical trials. Not only does this lead to a more innovative and resilien...